Appendix 4C

31 January 2018

Melbourne, Australia and Leatherhead, UK

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe and therapeutically unmet genetic disorders today announced its Appendix 4C – Quarterly Cashflow report for the period 01 October to 31 December 2017.

Download PDF to read more

We use cookies to give you the best experience.